In 2024, DaShenLin Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, DaShenLin Pharmaceutical Group has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 |
|---|---|
Total Scope 1 | 5,220.48a |
Total Scope 2 | |
Unspecified Calculation Method | 14,082.59a |
Total Scope 3 | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 1.4379a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of DaShenLin Pharmaceutical Group amounted to 19,303.07 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
In 2024, the total Scope 1 emissions of DaShenLin Pharmaceutical Group were 5,220.48 metric tons of CO₂ equivalent (tCO₂e).a
In 2024, DaShenLin Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 14,082.59 tCO₂e without specifying the calculation method.a
In 2024, DaShenLin Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology.a
In 2024, DaShenLin Pharmaceutical Group reported Scope 1 greenhouse gas (GHG) emissions of 5,220.48 tCO₂e and total revenues of USD 3,631 millions. This translates into an emissions intensity of 1.44 tCO₂e per millions USD.a
In 2024, DaShenLin Pharmaceutical Group reported a Scope 1 emissions intensity of 1.44 tCO₂e per millions USD. Compared to the peer group median of 1.58, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, DaShenLin Pharmaceutical Group ranked 12 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
DaShenLin Pharmaceutical Group is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a